DK1505974T3 - Anvendelse af forbindelser, der er effektive som selektive opiatreceptormodulatorer - Google Patents
Anvendelse af forbindelser, der er effektive som selektive opiatreceptormodulatorerInfo
- Publication number
- DK1505974T3 DK1505974T3 DK03752716T DK03752716T DK1505974T3 DK 1505974 T3 DK1505974 T3 DK 1505974T3 DK 03752716 T DK03752716 T DK 03752716T DK 03752716 T DK03752716 T DK 03752716T DK 1505974 T3 DK1505974 T3 DK 1505974T3
- Authority
- DK
- Denmark
- Prior art keywords
- compounds
- effective
- receptor modulators
- opiate receptor
- selective opiate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02011047 | 2002-05-17 | ||
PCT/EP2003/004428 WO2003097051A2 (en) | 2002-05-17 | 2003-04-28 | Use of compounds that are effective as selective opiate receptor modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1505974T3 true DK1505974T3 (da) | 2009-08-17 |
Family
ID=29433078
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK03752716T DK1505974T3 (da) | 2002-05-17 | 2003-04-28 | Anvendelse af forbindelser, der er effektive som selektive opiatreceptormodulatorer |
Country Status (21)
Country | Link |
---|---|
US (1) | US20050176746A1 (da) |
EP (2) | EP2074997A1 (da) |
JP (1) | JP2005531557A (da) |
KR (1) | KR101108014B1 (da) |
CN (2) | CN100411618C (da) |
AR (1) | AR040028A1 (da) |
AT (1) | ATE429226T1 (da) |
AU (1) | AU2003242527B2 (da) |
BR (1) | BR0309969A (da) |
CA (1) | CA2486000A1 (da) |
DE (1) | DE60327315D1 (da) |
DK (1) | DK1505974T3 (da) |
ES (1) | ES2325782T3 (da) |
HK (1) | HK1079451A1 (da) |
MX (1) | MXPA04011333A (da) |
PE (1) | PE20040455A1 (da) |
PL (1) | PL371596A1 (da) |
RU (1) | RU2336871C2 (da) |
TW (1) | TWI314053B (da) |
WO (1) | WO2003097051A2 (da) |
ZA (1) | ZA200410160B (da) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10259245A1 (de) * | 2002-12-17 | 2004-07-01 | Merck Patent Gmbh | Derivate des Asimadolins mit kovalent gebundenen Säuren |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
EP1594517B1 (en) | 2003-01-28 | 2007-06-20 | Microbia, Inc. | Compositions for the treatment of gastrointestinal disorders |
EP1870096A3 (en) * | 2003-04-29 | 2011-04-20 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss |
MXPA05011557A (es) | 2003-04-29 | 2006-03-09 | Orexigen Therapeutics Inc | Composiciones para afectar perdida de peso. |
CA2544245A1 (en) * | 2003-10-30 | 2005-05-26 | Tioga Pharmaceuticals, Inc. | Use of selective opiate receptor modulators in the treatment of neuropathy |
CA2630624C (en) | 2005-11-22 | 2013-08-06 | Orexigen Therapeutics, Inc. | Compositions and methods for increasing insulin sensitivity |
US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
KR20180066272A (ko) | 2006-11-09 | 2018-06-18 | 오렉시젠 세러퓨틱스 인크. | 단위 용량 팩키지 |
BRPI0809651A2 (pt) * | 2007-03-30 | 2014-10-07 | Tioga Pharmaceuticals Inc | Agonistas de kappa-opiato para o tratamento de síndrome do cólon irritável de diarreia predominante ou alternada |
WO2008151257A2 (en) | 2007-06-04 | 2008-12-11 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
CA2725930A1 (en) | 2008-05-30 | 2009-12-30 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
EP2328910B1 (en) | 2008-06-04 | 2014-08-06 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
AU2009270833B2 (en) | 2008-07-16 | 2015-02-19 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
US20100221329A1 (en) | 2008-12-03 | 2010-09-02 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase c agonists and methods of use |
WO2018129556A1 (en) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
WO2010078449A2 (en) | 2008-12-31 | 2010-07-08 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
MX344303B (es) | 2010-01-11 | 2016-12-13 | Orexigen Therapeutics Inc | Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor. |
US9303027B2 (en) | 2010-07-19 | 2016-04-05 | Dr. Reddy's Laboratories Ltd. | Kappa opioid receptor agonists |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
CA3100941C (en) | 2011-03-01 | 2024-03-05 | Synergy Pharmaceuticals Inc. | Process of preparing guanylate cyclase c agonists |
IL300868A (en) | 2012-06-06 | 2023-04-01 | Orexigen Therapeutics Inc | Methods for treating overweight and obesity |
US20150336892A1 (en) | 2012-08-21 | 2015-11-26 | Ardelyx, Inc | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
US10376481B2 (en) | 2012-08-21 | 2019-08-13 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
US9675587B2 (en) | 2013-03-14 | 2017-06-13 | Allergan Holdings Unlimited Company | Opioid receptor modulator dosage formulations |
CA2905438A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
EP2968439A2 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
EP3552630A1 (en) | 2013-04-12 | 2019-10-16 | Ardelyx, Inc. | Nhe3-binding compounds for inhibiting phosphate transport |
US10011637B2 (en) | 2013-06-05 | 2018-07-03 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
EA023231B1 (ru) * | 2013-07-18 | 2016-05-31 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт нормальной физиологии имени П.К. Анохина" Российской академии медицинских наук (ФГБУ "НИИНФ им. П.К. Анохина" РАМН) | Применение агониста каппа опиоидных рецепторов периферического действия ici 204,448 для приготовления средств для лечения синдрома отмены никотина |
WO2015065867A2 (en) * | 2013-10-28 | 2015-05-07 | Cara Therapeutics, Inc. | Peripheral kappa opioid receptor agonists for preventing, inhibiting or treating nausea and vomiting |
US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
WO2018129557A1 (en) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Inhibitors of nhe-mediated antiport |
CN110267944B (zh) | 2017-01-09 | 2024-03-08 | 阿德利克斯股份有限公司 | 可用于治疗胃肠道病症的化合物 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4889860A (en) * | 1985-09-23 | 1989-12-26 | Nova Pharmaceutical Corporation | Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists |
DE3935371A1 (de) | 1988-12-23 | 1990-07-05 | Merck Patent Gmbh | Stickstoffhaltige ringverbindungen |
DE4034785A1 (de) | 1990-11-02 | 1992-05-07 | Merck Patent Gmbh | 1-(2-arylethyl)-pyrrolidine |
US5389686A (en) * | 1989-02-20 | 1995-02-14 | Jouveinal Sa | Analgesic properties of fedotozine |
DE4215231C1 (en) | 1992-05-09 | 1993-05-13 | Dornier Luftfahrt Gmbh, 8031 Wessling, De | Arrangement for mfg. fibre reinforced thermoplastic components - including unit for accommodating component, pressurising unit for assembled component and heating unit |
DE4215213A1 (de) | 1992-05-09 | 1993-11-11 | Merck Patent Gmbh | Arylacetamide |
DE19523502A1 (de) * | 1995-06-28 | 1997-01-02 | Merck Patent Gmbh | Kappa-Opiatagonisten für entzündliche Darmerkrankungen |
DE19531464A1 (de) * | 1995-08-26 | 1997-02-27 | Merck Patent Gmbh | N-Methyl-N-[(1S-)-1-phenyl-2-((3S)-3-hydroxypyrrolidin 1-yl-)-ethyl]-2,2-diphenyl-acetamid |
EP1021204B1 (en) * | 1997-09-26 | 2005-12-28 | Noven Pharmaceuticals, Inc. | Bioadhesive compositions and methods for topical administration of active agents |
US20010051181A1 (en) * | 1997-12-22 | 2001-12-13 | Van Osdol William W. | Novel formulations for the transdermal administration of asimadoline |
JPH11343244A (ja) * | 1998-03-30 | 1999-12-14 | Taisho Pharmaceut Co Ltd | 経口用組成物 |
JP2000080047A (ja) * | 1998-06-30 | 2000-03-21 | Takeda Chem Ind Ltd | 医 薬 |
DE69933771T2 (de) * | 1998-07-14 | 2007-09-13 | Janssen Pharmaceutica N.V. | Neurotrophischer wachstumsfaktor |
ATE289586T1 (de) * | 1999-03-01 | 2005-03-15 | Pfizer Prod Inc | Oxamsäuren mit einer cyanogruppe als liganden für den thyroidrezeptor |
AU2001266988A1 (en) * | 2000-06-19 | 2002-01-02 | Eisai Co. Ltd. | Novel methods using pyridine derivatives |
GB0015562D0 (en) * | 2000-06-23 | 2000-08-16 | Pfizer Ltd | Heterocycles |
US6262062B1 (en) * | 2000-08-15 | 2001-07-17 | Cpd, Llc | Method of treating the syndrome of coronary heart disease risk factors in humans |
US6569449B1 (en) * | 2000-11-13 | 2003-05-27 | University Of Kentucky Research Foundation | Transdermal delivery of opioid antagonist prodrugs |
WO2003048113A1 (en) * | 2001-11-30 | 2003-06-12 | Sepracor Inc. | Tramadol analogs and uses thereof |
-
2003
- 2003-04-28 CA CA002486000A patent/CA2486000A1/en not_active Abandoned
- 2003-04-28 BR BR0309969-5A patent/BR0309969A/pt not_active Application Discontinuation
- 2003-04-28 CN CNB038111373A patent/CN100411618C/zh not_active Expired - Fee Related
- 2003-04-28 DE DE60327315T patent/DE60327315D1/de not_active Expired - Lifetime
- 2003-04-28 PL PL03371596A patent/PL371596A1/xx not_active Application Discontinuation
- 2003-04-28 KR KR1020047018468A patent/KR101108014B1/ko not_active IP Right Cessation
- 2003-04-28 EP EP09158047A patent/EP2074997A1/en not_active Withdrawn
- 2003-04-28 WO PCT/EP2003/004428 patent/WO2003097051A2/en active Application Filing
- 2003-04-28 CN CNA2008101295692A patent/CN101310723A/zh active Pending
- 2003-04-28 DK DK03752716T patent/DK1505974T3/da active
- 2003-04-28 EP EP03752716A patent/EP1505974B1/en not_active Expired - Lifetime
- 2003-04-28 MX MXPA04011333A patent/MXPA04011333A/es active IP Right Grant
- 2003-04-28 US US10/514,887 patent/US20050176746A1/en not_active Abandoned
- 2003-04-28 RU RU2004137091/15A patent/RU2336871C2/ru not_active IP Right Cessation
- 2003-04-28 ES ES03752716T patent/ES2325782T3/es not_active Expired - Lifetime
- 2003-04-28 AU AU2003242527A patent/AU2003242527B2/en not_active Ceased
- 2003-04-28 AT AT03752716T patent/ATE429226T1/de not_active IP Right Cessation
- 2003-04-28 JP JP2004505050A patent/JP2005531557A/ja active Pending
- 2003-05-12 TW TW092112843A patent/TWI314053B/zh not_active IP Right Cessation
- 2003-05-13 PE PE2003000457A patent/PE20040455A1/es not_active Application Discontinuation
- 2003-05-16 AR ARP030101709A patent/AR040028A1/es unknown
-
2004
- 2004-12-15 ZA ZA2004/10160A patent/ZA200410160B/en unknown
-
2005
- 2005-12-19 HK HK05111679.0A patent/HK1079451A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ATE429226T1 (de) | 2009-05-15 |
CN101310723A (zh) | 2008-11-26 |
ES2325782T3 (es) | 2009-09-17 |
RU2336871C2 (ru) | 2008-10-27 |
US20050176746A1 (en) | 2005-08-11 |
PE20040455A1 (es) | 2004-08-07 |
AU2003242527A1 (en) | 2003-12-02 |
DE60327315D1 (de) | 2009-06-04 |
PL371596A1 (en) | 2005-06-27 |
EP1505974B1 (en) | 2009-04-22 |
RU2004137091A (ru) | 2005-09-10 |
WO2003097051A3 (en) | 2004-12-09 |
AR040028A1 (es) | 2005-03-09 |
AU2003242527B2 (en) | 2008-10-23 |
MXPA04011333A (es) | 2005-02-14 |
CA2486000A1 (en) | 2003-11-27 |
KR101108014B1 (ko) | 2012-01-25 |
CN100411618C (zh) | 2008-08-20 |
TWI314053B (en) | 2009-09-01 |
HK1079451A1 (en) | 2006-04-07 |
CN1655784A (zh) | 2005-08-17 |
KR20050010807A (ko) | 2005-01-28 |
EP1505974A2 (en) | 2005-02-16 |
WO2003097051A2 (en) | 2003-11-27 |
EP2074997A1 (en) | 2009-07-01 |
ZA200410160B (en) | 2005-12-28 |
JP2005531557A (ja) | 2005-10-20 |
BR0309969A (pt) | 2005-04-26 |
TW200307541A (en) | 2003-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1505974T3 (da) | Anvendelse af forbindelser, der er effektive som selektive opiatreceptormodulatorer | |
LTPA2017005I1 (lt) | Nauji junginiai, kaip opioido receptoriaus moduliatoriai | |
DK1668014T3 (da) | Kondenserede heterocykliske forbindelser som serotoninreceptormodulatorer | |
DK1592658T3 (da) | Syntese af selektive, androgene receptormodulatorer i stor målestok | |
DK1656345T3 (da) | Cykliske derivater som modulatorer af chemokinreceptoraktivitet | |
NO20051042L (no) | Pyrimidylsulfonamidderivater som kemokinreseptormodulatorer | |
DK1833799T3 (da) | 3-phenyl-pyrazol derivater, som modulatorer af 5-HT-2a-serotonin receptor nyttig til behandlingen af sygdomme relateret hertil | |
DE60325025D1 (de) | Modulatoren des vanilloidrezeptors | |
DK2060570T3 (da) | Som modulatorer af dopamin-d3-receptorer anvendelige azabicyclo(3.1.0)hexanderivater | |
DK2208727T3 (da) | Diarylethere som opioidreceptorantagonister | |
DK1521733T3 (da) | Modulatorer af glucocorticoid receptoren | |
DK1651621T3 (da) | 2-(Quinoxalin-5-ylsulfonylamino)benzamidforbindelser som CCK2-modulatorer | |
DK1817309T3 (da) | Acetamidforbindelser som fungicider | |
NO20054951D0 (no) | Prostaglandinanaloger som EP4-reseptorantagonister | |
DK1339678T3 (da) | Selektive agonister til EP4-receptor til behandling af osteoporose | |
DK1663996T3 (da) | (Thio)carbamoylcyclohexanderivater som D3/D2-receptorantagonister | |
DK1501826T3 (da) | Substituerede indoler som alpha-1-agonister | |
DK1414440T3 (da) | N-phenylpyrrolguanidinderivater som melanocortinreceptorligander | |
NO20044654L (no) | Piperidinoylpiperidiner som 5-HTIF-agonister | |
NO20052884D0 (no) | Substituerte indolpyridinforbindelser som anti-infeksjonsmidler. | |
NO20052797D0 (no) | Fenyl eller heteroaryl aminoalkanderivater som IP-reseptorantagonister | |
DK1404667T3 (da) | Piperidinderivater, der er anvendelige som modulatorer af chemokinreceptoraktivitet | |
ATE544762T1 (de) | Calcium rezeptor modulatoren | |
DK1506190T3 (da) | (Imidazol-1-yl-methyl)-pyridazin som NMDA-receptor-blokker | |
DK1778243T3 (da) | Substituerede azepinderivater som serotoninreceptormodulatorer |